KPTI Karyopharm Therapeutics Inc.

0  0%
Previous Close 11.72
Open 11.72
Price To book 3.03
Market Cap 488.98M
Shares 41,901,000
Volume 109,774
Short Ratio 5.85
Av. Daily Volume 298,561

SEC filingsSee all SEC filings

  1. 8-K - Current report 17742676
  2. 8-K - Current report 17741023
  3. 8-K - Current report 17738242
  4. 8-K - Current report 17734347
  5. S-8 - Securities to be offered to employees in employee benefit plans 17692907

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 updated data presented at ASH 2016.
Selinexor - SAIL
Acute myeloid leukemia (AML)
Phase 2 initiated April 2014. Interim data at ASCO 2015
Selinexor - (KING study)
Cancer - glioblastoma
Phase 2/3 trial initiated January 2016. Top-line data for the Phase 2 portion due mid-2017.
Selinexor - SEAL
Dedifferentiated liposarcoma
Phase 2 positive top-line data released September 6, 2016. Updated data at ASH 2016. Top-line data from expansion cohort due early 2018.
Selinexor - STORM
Quadruple Refractory Multiple Myeloma
Phase 1/2 updated data at ASH 2016. Phase 3 trial to be initiated early 2017.
Selinexor - STOMP
Multiple myeloma
Phase 2b additional interim data released April 4, 2017 at AACR. Final top-line data due mid-2018.
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Data Safety Monitoring Board (DSMB) noted March 2, 2017 that trial will not meet primary endpoint.
Selinexor SOPRA
Cancer - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 2 data presented at ASCO 2015. Phase 3 trial to be initiated late 2017.
Selinexor (SIGN Study)
Cancer - Advanced Gynecologic Malignancies (SIGN Study)
Phase 2 trial terminated.
Selinexor - SIRRT
Richter's transformation
Phase 2 trial terminated.
Selinexor - SHIP
Cancer - hormone-refractory prostate cancer (HRPC)

Latest News

  1. Six Stocks Spiking Up With Huge Volume
  2. Karyopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : KPTI-US : April 12, 2017
  3. Why Karyopharm Therapeutics Inc Stock Gained 16.4% in March
  4. Karyopharm Reports Interim Phase 2b SADAL Data at the 2017 American Association for Cancer Research Annual Meeting
  5. Karyopharm and Medidata Expand Clinical Trial Partnership
  6. Karyopharm Announces Management Change
  7. Karyopharm to Present Selinexor Phase 2b SADAL Data at the American Association for Cancer Research Annual Meeting 2017
  8. U.S. FDA Division of Hematology Products Lifts Partial Clinical Hold on Karyopharm’s Selinexor Clinical Trials
  9. Karyopharm to Present at the 16th Annual Needham Healthcare Conference
  10. Karyopharm Therapeutics, Inc. :KPTI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  11. Karyopharm Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : KPTI-US : March 21, 2017
  12. Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded
  13. Edited Transcript of KPTI earnings conference call or presentation 16-Mar-17 12:30pm GMT
  14. Karyopharm Therapeutics posts 4Q loss
  15. Karyopharm Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Selinexor Clinical Update
  16. ​FDA tells Newton biotech Karyopharm to pause new trial patient enrollment
  17. Karyopharm Announces Partial Clinical Hold to Pause Enrollment in Selinexor Trials
  18. Karyopharm to Report Fourth Quarter and Year End 2016 Financial Results on March 16, 2017
  19. Karyopharm Follows Juno With Leukemia Drug Dud; Stock Topples
  20. ​Shares of Newton’s Karyopharm slump as lead drug flunks trial